News

December 8, 2020December 8, 2020

Phase 2 Trial Begins Testing VS-6766, Defactinib Combo in Low-grade Serous Ovarian Cancer

News

Verastem Oncology has started a Phase 2 clinical trial evaluating its inhibitors, VS-6766 and defactinib, for the treatment of people with recurrent low-grade serous ovarian cancer (LGSOC), the company announced. ... Read more

December 3, 2020December 3, 2020

CRISPR-Cas9 in Lipid Nanoparticles Found to Safely Treat Ovarian Cancer in Mice

News

For the first time, researchers safely and effectively treated cells and mice with ovarian cancer using the CRISPR-Cas9 gene-editing tool plus a newly developed lipid nanoparticle (LNP) delivery system, which ... Read more

December 1, 2020December 1, 2020

Assisted Reproductive Technology Does Not Raise Risk of Ovarian Cancer, Study Indicates

News

Women who use assisted reproductive technology to help them conceive a child appear not to be at an increased risk of developing ovarian cancer, a nationwide study conducted in the ... Read more

November 26, 2020November 25, 2020

New $100M Program Aims to Improve Diversity in Clinical Trials

News, syndicated

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved patient ... Read more

November 24, 2020November 24, 2020

ALKS 4230-Keytruda Combo Found to Reduce Tumor Size, Halt Disease Progression

News

The combination of Keytruda (pembrolizumab) and ALKS 4230 was able to halt disease progression and reduce tumor size in a small group of heavily pre-treated patients with advanced ovarian cancer, ... Read more

November 19, 2020November 19, 2020

Study to Examine if Blood Test Can Detect Cancer Early in Low-Risk Women

News

The University of Texas’ MD Anderson Cancer Center, in collaboration with the National Cancer Institute and Golfers Against Cancer, is evaluating the usefulness of a blood test called CA-125 at detecting ovarian cancer ... Read more

November 17, 2020November 17, 2020

ImmunoGen Teams Up With Huadong Medicine to Develop Mirvetuximab in China

News

ImmunoGen has announced a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co, a subsidiary of Huadong Medicine, to develop and commercialize the ovarian cancer treatment mirvetuximab soravtansine to patients in China, ... Read more

November 12, 2020November 12, 2020

CA125 Blood Test Useful in Diagnosing Ovarian Cancer in Routine Setting

News

A blood test measuring levels of the protein cancer antigen 125 (CA125) can help detect ovarian cancer in a primary care setting with considerable accuracy, a study reported. The research ... Read more

November 10, 2020January 12, 2021

Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer

News

The European Commission has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more

November 5, 2020November 5, 2020

First Patient Dosed in Phase 2 Study of Cancer Vaccine Combination in Ovarian Cancer

News

The first patient has been dosed in a Phase 2 extension study investigating the cancer vaccine DSP-7888 (ombipepimut-S) in combination with the checkpoint inhibitor Keytruda (pembrolizumab), in people with platinum-resistant ... Read more